

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)



(10) International Publication Number
WO 2023/056305 A1

(51) International Patent Classification:

A61K 38/16 (2006.01) A61P 19/02 (2006.01)
A61K 38/39 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/US2022/077192

(22) International Filing Date:

28 September 2022 (28.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/249,552 28 September 2021 (28.09.2021) US
63/322,379 22 March 2022 (22.03.2022) US
63/337,274 02 May 2022 (02.05.2022) US

(71) Applicant: **VIELA BIO, INC.** [US/US]; 1 Horizon Way, Deerfield, Illinois 60015 (US).

(72) Inventors: **ILLEI, Gabor**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **ALEVIZOS, Ilias**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **WANG, Liangwei**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **FALLOON, Judith**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US). **REES, William**; c/o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015 (US).

(74) Agent: **BROWN, Fraser et al.**; COOLEY LLP, 1299 Pennsylvania Avenue NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS



N = total number of subjects planned for each cohort.

FIG. 1

(57) Abstract: A human CD40L-specific Tn3 molecule and therapeutic uses thereof for the treatment of autoimmune disease (e.g., rheumatoid arthritis).